St. Jude receives CE Mark, FDA nod for HIFU cardiac ablation system

St. Jude Medical has received European CE Mark approval and FDA clearance for the Epicor LP cardiac ablation system, a second generation technology that uses high-intensity focused ultrasound (HIFU) for cardiac ablation surgical procedures.

In surgical ablation performed with a HIFU energy source, the company said that the energy is focused from outside a beating heart. The treatment has been designed to create precise and complete lines of cardiac tissue ablation to block chaotic electrical impulses. HIFU energy is directed from outside the heart inward, minimizing the risk of unintended peripheral damage, according to the St. Paul, Minn.-based company.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.